GVBL.BO · BSE

GENOMIC VALLEY BIOTECH LIMITED

₹28.73

-4.99% (-₹1.51)

Prev. close

₹30.24

Volume

723

As of

18 Sept 2026

Price history

₹28.73-₹2.26 (-7.29%) · 3M
16 Jun 202618 Sept 2026
₹35.11₹27.216 Jun09 Jul03 Aug26 Aug18 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on GENOMIC VALLEY BIOTECH LIMITED in the last 90 days.

Fundamentals

About GENOMIC VALLEY BIOTECH LIMITED

Genomic Valley Biotech Limited operates in horticulture business activities in India. The company involved in the commercial greenhouse/poly house cultivation of crops; commercial horticulture activities with aloe vera, tomato, bitter gourd, bottle gourd, brinjal, broccoli, cabbage, capsicum, carrot, cauliflower, cucumber, green chilies, onion, radish, ridge/sponge gourd, leafy vegetables, pumpkin, banana, guava, papaya, and strawberry; and commercial floriculture of flowers. It also undertakes contracts for its clients for erecting greenhouses; and provides turnkey consultancy services. In addition, the company manufactures and markets bio-fertilizers; and offers farmer support apps. Further, it is involved in the operation of plant tissue culture process laboratory to produce tissue cultured plantlets. The company was incorporated in 1994 and is based in Delhi, India.

Details

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Yogesh Agrawal

Headquarters

Delhi

Key stats

Market cap

₹8.78 Cr

P/E ratio (TTM)

410.4

EPS (TTM)

₹0.07

Beta (1Y · daily vs NIFTY 50)

0.43

Beta (5Y · monthly vs NIFTY 50)

0.37

Shares float

7.16 L

EPS · quarter ended Jun 2026

₹0.05

Financial Performance

01 · Financials

-2 Cr0 Cr2 Cr4 Cr-2000%0%2000%4000%FY21FY22FY23FY24FY25FY26
RevenueNet incomeRevenue growth YoY

Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.

02 · Earnings Per Share (EPS)

-2024FY21FY22FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-2000%0%2000%4000%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr2 Cr4 Cr6 Cr0.05×0.1×0.15×0.2×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr2 Cr4 Cr6 CrFY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-100 L-50 L0 L50 LFY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹20.80 L₹7.10 L₹2.72 Cr₹16.51 L₹84.39 L₹26.75 L
EBITDA₹65.70 L₹1.67 L₹44.40 L₹4.37 L
₹-55.90 L₹-90,000₹64.83 L₹1.52 L₹35.61 L₹3.03 L
Diluted EPS₹-1.83₹-0.03₹2.12₹0.05₹1.17₹0.1

Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹4.42 Cr₹4.33 Cr₹4.36 Cr₹4.25 Cr
₹0₹0₹0₹0
Stockholders' equity₹3.53 Cr₹3.54 Cr₹3.90 Cr₹3.93 Cr

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated. Inventory shows ₹0 for 2023-03-31, 2024-03-31 — this deck's own annual-report reading has no Inventory figure for this filer in any year shown (2023-03-31, 2024-03-31, 2021-03-31, 2022-03-31 alike); the ₹0 shown here comes from this filer's own reported data feed rather than this deck's own extraction, and is positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies) rather than a display default. 2021-03-31, 2022-03-31 have no Inventory figure reaching this deck at all — not shown as zero, not shown as positive — left blank rather than assumed to match the other years.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹-77.87 L₹-2.01 L₹2.69 L₹-1.90 L
Investing cash flow₹1.52 Cr₹-1.52 L₹1.20 L₹0
₹-70.45 L₹0₹0₹0
Capital expenditure₹-91,763
End cash position₹4.13 L₹60,734₹4.52 L₹2.62 L

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%
GENOMIC VALLEY BIOTECH LIMITED₹9.24 Cr₹30.24432.02.350.8%0.00-68.3%-18.9%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

No stock news captured yet.